Ignite Creation Date:
2024-05-05 @ 9:27 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00005096
Status:
COMPLETED
Last Update Posted:
2017-07-14
First Post:
2000-04-06
Brief Title:
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
99-193
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Mary-Ellen Taplin MD
Responsible Party Title:
Taplin Mary-Ellen
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Rhone-Poulenc Rorer | INDUSTRY |
| National Cancer Institute NCI | NIH |